These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Lussier FZ; Benedet AL; Therriault J; Pascoal TA; Tissot C; Chamoun M; Mathotaarachchi S; Savard M; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Bezgin G; Kang MS; Fernandez Arias J; Wang YT; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P; Brain Commun; 2021; 3(2):fcab073. PubMed ID: 33959711 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604 [TBL] [Abstract][Full Text] [Related]
8. The dynamics of plasma biomarkers across the Alzheimer's continuum. Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875 [TBL] [Abstract][Full Text] [Related]
9. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835 [TBL] [Abstract][Full Text] [Related]
10. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781 [TBL] [Abstract][Full Text] [Related]
14. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum. Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667 [TBL] [Abstract][Full Text] [Related]
15. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Shen XN; Huang YY; Chen SD; Guo Y; Tan L; Dong Q; Yu JT; Transl Psychiatry; 2021 Nov; 11(1):585. PubMed ID: 34775468 [TBL] [Abstract][Full Text] [Related]
16. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Murray ME; Moloney CM; Kouri N; Syrjanen JA; Matchett BJ; Rothberg DM; Tranovich JF; Sirmans TNH; Wiste HJ; Boon BDC; Nguyen AT; Reichard RR; Dickson DW; Lowe VJ; Dage JL; Petersen RC; Jack CR; Knopman DS; Vemuri P; Graff-Radford J; Mielke MM Mol Neurodegener; 2022 Dec; 17(1):85. PubMed ID: 36575455 [TBL] [Abstract][Full Text] [Related]
17. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study. Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J; Front Neurol; 2021; 12():695696. PubMed ID: 34557143 [No Abstract] [Full Text] [Related]
18. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632 [TBL] [Abstract][Full Text] [Related]
19. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. Huang Y; Li Y; Xie F; Guo Q CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638 [TBL] [Abstract][Full Text] [Related]
20. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. Stocker H; Beyer L; Perna L; Rujescu D; Holleczek B; Beyreuther K; Stockmann J; Schöttker B; Gerwert K; Brenner H Alzheimers Dement; 2023 Jan; 19(1):25-35. PubMed ID: 35234335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]